✦ LIBER ✦

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

✍ Scribed by Ansell, S. M.; Horwitz, S. M.; Engert, A.; Khan, K. D.; Lin, T.; Strair, R.; Keler, T.; Graziano, R.; Blanset, D.; Yellin, M.; Fischkoff, S.; Assad, A.; Borchmann, P.

Book ID: 124062164
Publisher: American Society of Clinical Oncology
Year: 2007
Tongue: English
Weight: 123 KB
Volume: 25
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2006.07.8972

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II study of SGN-30 (anti-CD30 mA

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

✍ Andres Forero-Torres; John P. Leonard; Anas Younes; Joseph D. Rosenblatt; Paulin 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

Chimeric anti-CD20 monoclonal antibody (

Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial – Intergroup Collaborative Study

✍ M. van Oers; A. Hagenbeek; M. Van Glabbeke; I. Teodorovic 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 141 KB

Immunotherapy with FBTA05 (Bi20), a trif

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

✍ Raymund Buhmann, Stanglmaier Michael, Hess Juergen… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 328 KB